JP2024546641A - 免疫細胞へのインビボ送達 - Google Patents

免疫細胞へのインビボ送達 Download PDF

Info

Publication number
JP2024546641A
JP2024546641A JP2024533092A JP2024533092A JP2024546641A JP 2024546641 A JP2024546641 A JP 2024546641A JP 2024533092 A JP2024533092 A JP 2024533092A JP 2024533092 A JP2024533092 A JP 2024533092A JP 2024546641 A JP2024546641 A JP 2024546641A
Authority
JP
Japan
Prior art keywords
nucleic acid
car
receptor
domain
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546641A5 (https=
Inventor
マイケル クリチンスキー，
Original Assignee
カリスマ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリスマ セラピューティクス インコーポレイテッド filed Critical カリスマ セラピューティクス インコーポレイテッド
Publication of JP2024546641A publication Critical patent/JP2024546641A/ja
Publication of JP2024546641A5 publication Critical patent/JP2024546641A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by a specific adjuvant, e.g. cytokines or CpG
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024533092A 2021-12-09 2022-12-08 免疫細胞へのインビボ送達 Pending JP2024546641A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163287725P 2021-12-09 2021-12-09
US63/287,725 2021-12-09
PCT/US2022/052207 WO2023107593A2 (en) 2021-12-09 2022-12-08 In vivo delivery to immune cells

Publications (2)

Publication Number Publication Date
JP2024546641A true JP2024546641A (ja) 2024-12-26
JP2024546641A5 JP2024546641A5 (https=) 2026-01-07

Family

ID=86731192

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533092A Pending JP2024546641A (ja) 2021-12-09 2022-12-08 免疫細胞へのインビボ送達

Country Status (4)

Country Link
EP (1) EP4444361A4 (https=)
JP (1) JP2024546641A (https=)
AU (1) AU2022407035A1 (https=)
WO (1) WO2023107593A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313473A (en) 2021-12-15 2024-08-01 Interius Biotherapeutics Inc Pseudotyped viral particles, compositions comprising the same, and uses thereof
KR20250057777A (ko) 2022-07-25 2025-04-29 인테리우스 바이오테라퓨틱스, 인코포레이티드 돌연변이된 폴리펩티드, 이를 포함하는 조성물, 및 그 용도(mutated polypeptides, compositions comprising the same, and uses thereof)
CN117343908B (zh) * 2023-12-05 2024-02-09 南京大学 一种通过真菌精准激活的car-t细胞、制备方法、应用及药物组合物
WO2025235801A1 (en) 2024-05-08 2025-11-13 City Of Hope Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy
CN120695211A (zh) * 2025-06-25 2025-09-26 广东医科大学附属医院 mRNA组合物及其在制备肝纤维化治疗药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311901B2 (en) * 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
US10188749B2 (en) * 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3561053A1 (en) * 2018-04-26 2019-10-30 Baylor College of Medicine Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
CN114127297A (zh) * 2019-03-26 2022-03-01 加维什-加利里生物应用有限公司 遗传重编程的表达car的treg
IL295810B2 (en) * 2020-03-11 2026-01-01 Univ Pennsylvania Methods and compositions for gene delivery using a modified viral particle
JP7851254B2 (ja) * 2020-03-20 2026-04-24 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
CA3187138A1 (en) * 2020-06-26 2021-12-30 Carisma Therapeutics Inc. Mrna transfection of immune cells

Also Published As

Publication number Publication date
EP4444361A2 (en) 2024-10-16
EP4444361A4 (en) 2025-12-10
AU2022407035A1 (en) 2024-05-23
WO2023107593A3 (en) 2023-07-27
WO2023107593A2 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
JP7824235B2 (ja) キメラ抗原受容体のための新規コンストラクト
JP2024546641A (ja) 免疫細胞へのインビボ送達
JP2026026238A (ja) 免疫細胞のｍＲＮＡトランスフェクション
US20240299543A1 (en) Self-polarizing immune cells
US20250382350A1 (en) Switch receptors and modified immune cells
KR20250080888A (ko) 신규한 항메소텔린 키메라 항원 수용체 및 변형 면역 세포
WO2024030583A2 (en) Novel constructs for chimeric antigen receptors and uses thereof
WO2024129964A1 (en) Chimeric antigen receptors including jak/stat binding domains and modified immune cells
WO2024173329A2 (en) Chimeric antigen receptors including dap 10 and dap 12 domains and modified immune cells
WO2024233583A2 (en) Compositions and methods relating to intronic shrna chimeric antigen receptor constructs
WO2025111277A2 (en) Compositions and methods relating to redirected soluble modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251205